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 Abstract  
 
Interferon regulatory factor (IRF)-2 is a transcription factor involved in type I 
interferon (IFN-α/β) signaling. It has been reported that IRF-2 deficiency results in various 
immune dysfunctions. However, the role of IRF-2 in B cell functions needed to be elucidated. 
 Unlike wild type (WT) B cells, IRF-2-/- B2 cells were refractory to anti-IgM, but not 
LPS. Such a defect in proliferation was dependent on IFN-α/β receptor (IFNAR). Marginal 
zone B cells increased in the proportion relative to B2 cells in IRF-2-/- mice produced IgM 
normally to LPS stimulation. However, IRF-2-/- B2 cells were defective in IgM production in 
an IFNAR-independent manner, although both B cell subsets differentiated phenotypically to 
plasma cells at elevated efficiencies. Class switch recombination of IRF-2-/- B2 cells by LPS 
plus IL-4 was also impaired. Their reduced IgM production was conceivably due to an 
inefficient upregulation of Blimp-1. Consistent with these in vitro observations, specific 
antibody production in vivo to a T-dependent antigen by B2 cells was severely impaired in 
IRF-2-/- mice. However, a low, but significant, level of IgG was detected at a late time point, 
and this IgG exhibited comparable binding affinity to that in WT mice. Follicular helper T 
cell development and germinal center formation were normal. A similar tendency was 
observed when µ chain-/- mice were reconstituted with IRF-2-/- B cells. 
  These results revealed a multi-faceted role of IRF-2 in the function of B cells, 
particularly B2 cells, through regulating proliferation in an IFNAR-dependent manner and 




Interferon regulatory factors (IRFs) have been identified as regulators of human 
IFN-β gene and have been shown to play a pivotal role in IFN-α/β production and its 
signaling in the innate immune system (1,2). In addition, they control B cell development, 
activation and plasma cell (PC) differentiation in the adaptive immune responses (3). IRF-4 
and IRF-8 control immunoglobulin light chain gene rearrangement in the differentiation of   
B cells (4,5). IRF-8 also regulates pre-BCR expression (6) and differentiation to B2 and MZB 
cells in the spleen (7). Furthermore, IRF-4 and IRF-5 directly induce Prdm1 (coding Blimp-1) 
expression and initiate the PC development in the germinal centers (GC) (8,9).  
In the IRF family, IRF-2 was originally identified as an antagonist of IRF-1 (2,10). 
Further analyses revealed that IRF-2 competes with IFN-stimulated gene factor (ISGF) 3, 
hetero-trimer of STAT-1, STAT-2 and IRF-9, to bind ISGF-binding motif in promoters of 
IFN-α/β responsive genes, resulting in the suppression of IFN-α/β signals via IFNAR (2,11). 
This antagonistic function is important in order to attenuate IFN-α/β receptor 
(IFNAR)-dependent signals evoked by spontaneously produced IFN-α/β (12-15). In addition, 
IRF-2 binds to IFN-β and CIITA-pIV promoters and regulates their functions by competing 
with IRF-1 and Blimp-1 in cellular responses (16-18).  
Regarding immune cell development, IRF-2-/- mice have been shown to lack CD4+ 
dendritic cells (13,14) and NK cells (19) with spontaneous expansion of basophils (20). A 
previous study also shows that IRF-2-deficiency suppresses hematopoiesis and B 
lymphopoiesis in the bone marrow (21). However, detailed analyses of IRF-2 in mature B cell 
functions remains to be elucidated for proliferative and antibody (Ab) responses to 
thymus-dependent (TD) and thymus-independent type II (TI-2) antigens. 
Therefore, we aimed to investigate this issue. Our results show that IRF-2 affects 
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mainly B2, but not marginal zone B (MZB), cell functions in terms of anti-IgM-induced 




Materials and Methods 
 
Mice and immunization 
C57BL/6 were purchased from Japan SLC (Shizuoka, Japan). The generation of 
IRF-2-/-, IFNAR -/- and IRF-2-/-IFNAR-/- mice has been described previously (14). µ chain-/- 
mice (µMT) were kindly provided by Dr. Tomohiro Kurosaki (RCBI, Yokohama, Japan) and 
5 × 106 to 1 × 107 B cells were transferred into these mice 1 d before immunization. All mice 
were maintained under specific pathogen-free conditions and used at 6 - 10 weeks of age. 
Mice were immunized with 20 µg TNP-OVA in CFA (BD Biosciences, San Diego, CA, 
USA) or 20 µg trinitrophenyl (TNP)-Ficoll in PBS, and sera were collected at 0, 7 and 14 d. 
All experiments were performed according to the institutional Guidelines for Animal Use and 
Experimentation of Kyoto University. 
 
Antibodies and reagents 
FITC-anti-IgM was purchased from Roche Diagnostics (Hague Road, IN, USA). 
FITC-anti-CD4, PE-anti-CD3ε and PE-anti-CD21 were obtained from BD Biosciences. 
FITC-anti-CD23, PE-Cy7-anti-B220, biotin-anti-CXCR5 and biotin-anti-mouse IgM were 
from eBioscience (San Diego, CA, USA). F(ab´)2 goat anti-mouse IgM, Cy5-mouse anti-rat 
IgG, Streptavidin-Cy3, HRP-anti-rabbit IgG and AP-anti-mouse IgM and IgG were from 
Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Anti-IRF-4 and 
HRP-anti-actin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Streptavidin-Texas Red was from Molecular Probes (Eugene, OR, USA). TNP-Ficoll and 
TNP-BSA were from Biosearch Technologies (Novato, CA, USA). Biotin-PNA was 
purchased from Wako Inc. (Tokyo, Japan). Anti-CD4 (GK1.5), CD8 (53-6.7), CD11b 
(M1/70), CD16/32 (2.4G2), CD45R (B220), MHC class II (TIB120) and Gr-1 (RB6-8C5) 
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monoclonal antibodies (mAbs) were used as hybridoma supernatants. Purified anti-CD40 
(FGK45.2) and anti-CD43 (S7) mAbs were kind gifts from Dr. R. M. Steinman (Rockefeller 
University, NY, USA) and Dr. Koichi Ikuta (Kyoto University, Kyoto, Japan), respectively. 
 
Cell preparations, flowcytometry and immunohistochemistry 
Spleen and subcutaneous lymph node (LN) B cells were negatively enriched by 
anti-CD4, CD8, CD11b, CD43 and Gr-1 mAbs in combination with sheep anti-rat IgG 
Dynabeads (Dynal, Lake Success, NY, USA). The resulting cells consisted of >94% B220+ 
cells. In some experiments, purified B cells stained with anti-CD21, anti-CD23 and anti-B220 
were sorted for B2 cells as B220+CD23+CD21low and MZB cells as B220+CD23-CD21high by 
FACSAria (BD Biosciences). Preparation of CD4+ T cells was described previously (22). 
Cells from spleen were stained with the mAbs indicated in the figure legends and 
acquired using FACSCalibur (BD Biosciences). Data were analyzed by FlowJo software 
(Tree Star Inc., San Carlos, CA, USA). Immunohistochemistry was performed as described 
previously (22) using the mAbs indicated in the figure legends. 
 
In vitro culture and antibody production 
Purified B cells were cultured in 100 µl of RPMI1640 supplemented with 
heat-inactivated 5% FCS, 50 µM 2-mercaptoethanol (culture medium) at 1.5 × 105 cells/well 
in 96-well flat-bottomed plates, and stimulated with either 100 U/ml IL-4 (eBioscience), 15 
µg/ml F(ab´)2 goat anti-mouse IgM Ab, 10 µg/ml agonistic anti-CD40 mAb, 10 µg/ml LPS 
(Sigma-Aldrich, St. Louis, MO, USA) alone or their combination. Proliferation was assessed 
by [3H]-thymidine (TdR) incorporation between 40-48 h of culture. For Ab production, 1.5 × 
105 B cells were stimulated with 10 µg/ml LPS in the presence or absence of 1,000 U/ml IL-4 
for 3 d and the amounts of IgM and IgG1 in the culture supernatant were assessed by ELISA 
 728 
using plates coated with anti-mouse Ig Ab.  
 Anti-TNP Abs in serum were also assayed by ELISA using plates coated with 
TNP-BSA with serially diluted serum, followed by goat-anti-mouse IgM or IgG. Results are 
shown as an index, which was calculated by dividing the half-max optical density value of the 
serum dilution at 7 d and 14 d by that of 0 d. Affinity of Ab was calculated by dividing the 
half-max optical density value of the serum dilution to anti-TNP5-BSA by that to 
anti-TNP19-BSA at 7 d and 14 d. 
 
Detection of gene expression  
Quantitative RT-PCR was performed to detect gene expressions. Briefly, total RNA 
was extracted from B or T cells with TRIzol® (Invitrogen, Carlsbad, CA, USA). In some 
experiments, cDNA was generated with SuperScript® III (Invitrogen). Quantitative PCR was 
performed with QuantiTect SYBR Green PCR Kits (Qiagen, Valencia, CA, USA) or SsoFast 
EvaGreen Supermix (Bio-Rad Laboratories, Hercules, CA, USA). Data were collected by 
Rotor-gene 2000 (Qiagen), and the relative expression was quantified by comparative Ct 
assay. The following primers were used: 
Pax5: 5’-GTCCCCCAGTGCCGACACCA-3’ and 5’-AGCACCTCCAGCTGCTGCTG-3’, 
Blimp1: 5’-GCGCTGACGGGGGTACTTCTG-3’ and 
5’-CACCGATGAGGGGTCCAAAGCG-3’, IRF-4: 5’-TCTGCTGAAGCCTTGGCGCTC-3’ 
and 5’- TGTCCGTGGGAGATCCGGCA-3’, Bcl-6: 5’-ACGCTGCAGACGCACAGTGA-3’ 






5’-AGACGGCCGCATCTTCTTGTGC-3’ and 5’-GCCACTGCAAATGGCAGCCC-3’. 
 For Western blot analysis, B cell lysates were prepared before or after LPS 
stimulation with lysis buffer [1% Triton X-100, 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 
and 25 mM CaCl2]. Samples were separated by 12% SDS-PAGE, transferred to Immobilon-P 
membranes (Millipore, Bedford, MA, USA), probed with anti-IRF-4 Ab and HRP-anti-Rab 
IgG or HRP-anti-actin, and then visualized with LumiGLO chemiluminescent substrate (Cell 
Signaling Technology, Beverly, MA, USA).  
 
Transduction of IRF-2 cDNA to LPS-activated B2 B cells. 
 IRF-2 cDNA was cloned into MSCV-based retroviral vector (a gift from Dr. 
Tomohiro Kurosaki) containing EGFP downstream of the internal ribosomal entry site. The 
Plat-E packaging cells were transiently transfected with retroviral vector with the 
Lipofectamine 2000 reagent (Invitrogen) to produce viral supernatant. Purified B2 B cells 
from IRF-2-/- or and WT mice were stimulated with LPS for 1 d and transduced with 
retrovirus in the presence of 10 µg/ml polybrene. Two days after infection, EGFP+ cells were 
sorted and cultured at 3.5 to 5 × 104 cells/well without stimuli. The supernatant for ELISA 
and total RNA for RT-PCR were collected 3 d later. 
  
Statistical analysis 
 Data are expressed as the mean ± SD of triplicate cultures or the sum of individual 
experiments. Statistical significances were determined by the unpaired Student’s t-test or 
one-way ANOVA. Differences were considered to be significant for p values < 0.05. All 





Reduced proliferation of IRF-2-/- B cells in response to BCR-mediated stimulation in an 
IFNAR-dependent manner 
 We first examined B cell proliferative responses to various stimuli in vitro. Although 
B cells from both IRF-2-/- and WT mice responded comparably to LPS, IRF-2-/- B cells were 
severely impaired in their response to BCR-mediated stimulation (Fig. 1A). However, the 
IRF-2-/- B cells appeared to be better responders than WT B cells for agonistic anti-CD40 
mAb. 
 Since IRF-2 is involved in IFNAR-mediated signaling, the proliferative 
responsiveness of IRF-2-/- spleen B cells to anti-IgM was compared with that of 
IRF-2-/-IFNAR-/- B cells. As shown in Fig. 1B, the reduced B cell proliferation in IRF-2-/- 
mice was restored in IRF-2-/-IFNAR-/- mice to nearly comparable levels in WT and IFNAR-/- 
mice, implying that IRF-2 counteracts the IFNAR-dependent signals that inhibits 
BCR-induced proliferation. 
 
Decreased IgM production by LN, but not spleen, B cells in response to LPS 
LPS is a most potent mitogen for B cells to induce the proliferation and IgM 
production. Since LPS evoked comparable proliferation between WT and IRF-2-/- B cells, we 
next examined the IgM production by spleen and LN B cells from IRF-2-/-, IFNAR-/-, 
IRF-2-/-IFNAR-/- and WT mice. Ab production of spleen B cells appeared to be normal in all 
strains of mice (Fig. 1C, left panel), whereas LN B cells, which consist mainly of B2 cells, 
showed significantly decreased IgM production not only in IRF-2-/- but also in 
IRF-2-/-IFNAR-/- mice (Fig. 1C, right panel). These results indicate that, unlike the 
proliferation, the reduced Ab-producing ability of IRF-2-/- B2 cells is not mediated by 
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IFNAR-dependent signals.   
 
Skewed B cell development to MZB rather than to B2 in IRF-2-/- mice 
 It is well known that spleen B cells are comprised of B2 and MZB cells (23). A 
previous study has suggested that, in contrast to B2 cells in vitro, BCR stimulation leads to 
the apoptosis of MZB cells, and LPS treatment induces rapid and robust levels of proliferation 
and differentiation to Ab forming cells (24). Taking the results shown in Fig. 1C into account, 
it is plausible that the spleen B cell composition in IRF-2-/- mice is skewed to MZB cells. To 
examine this possibility, B cell populations were compared between IRF-2-/- and WT mice by 
gating on B220+ cells (Fig. 2A, left panels). MZB cells (CD21+CD23-) were a minor 
population in WT mice. In contrast, those in IRF-2-/- mice were markedly increased. In 
addition, the number of B2 cells in the IRF-2-/- mice was reduced to half that in the WT mice 
(Fig. 2A, right panels). However, the number of B cells in the LN was not significantly 
reduced in IRF-2-/- mice (data not shown). Increased MZB cells were also confirmed by their 
phenotype of IgM+IgD- as revealed in the immunochistochemical staining with anti-IgM and 
IgD (Fig. 2B, left panels), followed by measuring the thickness of MZ (Fig. 2B, right panel). 
Similar results were obtained by the staining of MZ macrophages with ER-TR9 mAb (data 
not shown).  
 
Defect in B2, but not MZB, cell responsiveness in IRF-2-/- mice 
 We then re-examined proliferative responsiveness of B2 and MZB cells separately  
(Fig.3A). The results showed that IRF-2-/- B2 cells were incapable of proliferating in response 
to anti-IgM, but responded to LPS more vigorously than WT B2 cells (Fig. 3A, left panel). As 
reported (25), both IRF-2-/- and WT MZB cells were unresponsive to BCR-dependent 
signaling but responded equally to LPS stimulation (Fig. 3A, right panel). Like B2 cells, 
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IRF-2-/- MZB cells looked to be more reactive to agonistic anti-CD40 mAb than WT MZB 
cells. However, the severe reduction of BCR-induced proliferation in IRF-2-/- B2 cells was 
partially restored by either IL-4 or anti-CD40 alone. When both IL-4 and anti-CD40 were 
added, IRF-2-/- B2 cells equally responded to WT B2 cells (Fig. 3B).  
 In regard to Ab production, the B2, but not MZB, cell response to LPS was 
significantly impaired in IRF-2-/- (Fig. 3C), although there was good proliferation (Fig. 3A). 
In contrast to Ab production, the differentiation to PC in phenotypes was unexpectedly 
augmented in IRF-2-/- B2 cells (Fig. 3D). This accelerated differentiation was also seen in 
IRF-2-/- MZB cells. As to class switch recombination (CSR) from IgM to IgG1, IRF-2-/- B2 
cells were less efficient and produced lower amounts of IgG1 than WT B2 cells when 
stimulated with LPS and IL-4 (Figs. 3E and 3F). These results show that the unresponsiveness 
of IRF-2-/- splenic B cells can be ascribed to the defect in the B2, but not MZB, cells, and 
indicate that IRF-2 expression is required for the BCR-mediated proliferation and 
LPS-induced differentiation into Ab-producing PC as well as CSR of B2 cells.  
  
Inefficient upregulation of Blimp-1 by LPS in IRF-2-/- B2 cells  
To explore the stage affected by IRF-2 deficiency in B cell differentiation into PC, 
we analyzed the mRNA expression of Pax5, Prdm1 (coding Blimp-1), Irf4, Bcl6 and Bach2 
in IRF-2-/- B2 cells. Prior to LPS stimulation, LN B cells from IRF-2-/- expressed comparable 
levels of Pax5, Prdm1, Irf4 and Bach2, but partial reduction of Bcl6 (Fig. 4A, top panels). 
After stimulation with LPS for 3 d, Pax5, Irf4, Bcl6 and Bach2 expression was downregulated 
in IRF-2-/- B2 as well as in WT B2 cells. Notably, upregulation of Prdm1, observed readily in 
WT B2 cells, was severely impaired in IRF-2-/- B2 cells. Interestingly, both IRF-2-/- and WT 
MZB cells, which were able to differentiate into PC (see Fig.3D), downregulated Pax5, Bcl6 
and Bach2, and upregulated Irf4 and Prdm1 mRNA (Fig. 4A, bottom panels). Furthermore, 
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stimulated B2 cells increased IRF-4 protein (Fig. 4B), although its mRNA was decreased in 
both IRF-2-/- and WT B2 cells (Fig. 4A).   
To confirm the role for IRF-2 in Blimp-1 induction and Ab production, we 
retrovirally transduced IRF-2 cDNA into IRF-2-/- B2 cells. Complementation of IRF-2 indeed 
augmented Blimp-1 expression (Fig. 4C) along with the elevation of Ab production (Fig. 4D). 
When WT B2 cells were transduced with IRF-2 cDNA, Blimp-1 expression was further 
upregulated (Fig. 4E), but IgM production was not affected (Fig. 4F). Perhaps the amounts of 
Blimp-1 in WT B2 cells were already sufficient to induce IgM production. These results 
suggest that IRF-2 is deeply involved in Prdm1 upregulation and Ab production in B2 cells.  
 
Reduced Ab production in response to TD, but not TI-2 antigen, in IRF-2-/- mice 
 To investigate the role of IRF-2 in B cell function in vivo, we examined the Ab 
producing ability against TNP-Ficoll, a TI-2 antigen, and TNP-OVA/CFA, a TD antigen. 
After a single injection of antigens, TNP-specific IgM and IgG in the sera of IRF-2-/- mice 
were compared at 7 and 14 d with those of WT mice. In response to TNP-Ficoll, IRF-2-/- and 
WT mice produced comparable levels of TNP-specific IgM and IgG (Fig. 5A). In sharp 
contrast, Ab production, particularly that of IgM, to TD antigen was severely impaired at 7 
and 14 d in the IRF-2-/- mice (Fig. 5B). Although the IgG production was severely reduced at 
7 d, it increased to significant, but still markedly low, levels as compared with those in WT 
mice at 14 d. Of note, the affinity maturation at 14 d was comparable between IRF-2-/- and 
WT mice (Fig. 5C). 
Since high-affinity IgG Ab in response to TD antigen is produced by PCs generated 
in the germinal center (GC) (26), GC formation was also examined in IRF-2-/- and WT mice. 
Immunohistochemical staining of spleen sections at 14 d with PNA and anti-IgD 
demonstrated that GC formation in IRF-2-/- mice was not severely impaired, although PNA+ 
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cells looked slightly sparse (Fig. 5D). However, GC B cells identified as PNA+Fas+ were not 
significantly reduced in IRF-2-/- mice compared with WT mice (Fig. 5E). In addition, there 
was no significant difference in apoptotic GC B cells between IRF-2-/- and WT mice (data not 
shown). Consistent with GC formation and normal GC B cell development, comparable 
numbers of follicular helper T (Tfh) cells were present in the IRF-2-/- spleen at 14 d (Fig. 5F). 
Moreover, IL-21 and Bcl-6 mRNA expression in CD4+ T cells was also comparable at 10 d 
between IRF-2-/- and WT (Fig. 5G). 
To verify that the profoundly reduced Ab-producing response to TD antigen in the 
IRF-2-/- mice could be attributed to B cell intrinsic defects, but not CD4+ T cell function, we 
transferred purified IRF-2-/- or WT B cells to µMT mice and immunized these mice with 
TNP-OVA/CFA (Fig. 5H). Neither IgM at 7 d nor IgG levels at 7 d or 14 d were fully 
restored in IRF-2-/- B cell-reconstituted mice, indicating that the impaired Ab response in the 
IRF-2-/- mice is due to intrinsic B cell defects. It should be noted that no measurable amounts 
of IgM were detected at 14 d in this experimental design (data not shown). These data suggest 
that IRF-2 is necessary for an optimal Ab response, likely at the level of antibody production, 




The present study demonstrates that IRF-2 is involved in B2, but not MZB, cell 
proliferation and differentiation into Ab-producing PC induced by in vitro stimulation with 
anti-IgM and LPS, respectively. Importantly, IRF-2 contributes to these two B2 cell functions 
through different mechanisms. As in in vitro assays, the IRF-2-/- mice responded normally to 
TI-2 Ag, but dramatically reduced IgM as well as IgG production in response to TD Ag in 
vivo.  
With respect to B cell proliferation, IRF-2 regulates BCR- but not LPS-induced 
signals by antagonizing IFNAR-mediated signaling, indicating that IFNAR signaling could 
act as an endogenous negative regulator of BCR-stimulated B cell proliferation. We did not 
directly examine the proliferative responses of purified B2 cells from IRF-2-/-IFNAR-/- mice. 
However, since MZB cells did not respond to anti-IgM stimulation irrespective of their 
genotype, anti-IgM-induced proliferation by IRF-2-/-IFNAR-/- splenic B cells, which is as 
strong as that by WT B cells, appears to be attributable to the restoration of B2 cell responses, 
indicating that IFN-α/β are an intrinsic attenuator of B2 cell proliferation. In support of this 
possibility, BCR-mediated proliferation of WT B2 cells was reduced when large amounts of 
exogenous IFN-α were added (data not shown). However, previous studies have shown that 
IFN-α/β positively controls BCR-mediated activation of immature and mature B cells and 
rescues them from cell death (27-29). Reconciling these apparently contradicting observations, 
we infer that IRF-2 sets a threshold for IFNAR signals, preventing too strong and/or chronic 
IFN-α/β signals from inhibiting B2 cell proliferation. 
Regarding the apparently skewed B cell development to MZB rather than to B2 cells 
in IRF-2-/- mice, the mechanisms involved are not clear. However, there is a similar B cell 
composition in IRF-2-/-IFNAR-/- and IRF-2-/-mice (data not shown). Therefore, an endogenous 
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IFN-α/β, or IFNAR-mediated signal seems not to be directly involved in spleen B cell 
development and survival in vivo. On the other hand, it has been reported that pre-B and 
immature B cell numbers are severely reduced in IRF-2-/- animals with a mixed background of 
C57BL/6 and 129 strains (21), and we also observed that apoptosis of differentiating B cells 
at the stage of pro- and pre-B cells in the bone marrow looked to be a little higher in IRF-2-/- 
than WT mice (data not shown), implying that IRF-2 plays a role in controlling B cell 
development in the early stages.  
IRF-2 in B2, but not MZB, cells is required for in vitro IgM production upon LPS 
stimulation. Blimp-1 is a master regulator of PC differentiation and is necessary for Ab 
secretion (30). In accordance with decreased IgM production by B2 cells, upregulation of 
Blimp-1 is impaired in IRF-2-/- LN B cells, which consist predominantly of B2 cells. Unlike 
B2 cells, IRF-2-/- MZB cells produced nearly comparable levels of IgM to WT MZB cells and 
upregulated Blimp-1 expression as efficiently as WT MZB cells. However, other 
transcriptional factors, such as Pax5, Bcl-6 and Bach2 including IRF-4, were similarly 
regulated in IRF-2-/- as in WT B2 cells.  
Other IRF family members, such as IRF-4 and IRF-5, have been shown to bind the 
Prdm1 promoter and to upregulate Blimp-1 expression (8,9). At this time point, there is no 
direct evidence for the direct binding of IRF-2 to the Prdm1 promoter. The impairment of 
Blimp-1 upregulation was also observed in IRF-2-/-IFNAR-/- B2 cells (data not shown). 
Furthermore, enforced expression of IRF-2 in IRF-2-/- B2 cells upregulated Blimp-1 
expression, indicating that IRF-2 is required for the induction of Blimp-1, acting on an as-yet 
unidentified signaling pathway other than those mediated by IFNAR. This 
IFNAR-independent IRF-2 function for Blimp-1 upregulation is also involved in LPS-induced 
IgM production by B2 cells, since LN B cells from IRF-2-/-IFNAR-/- mice were as inefficient 
as IRF-2-/- mice in IgM production, IgM production by LPS being restored by transduction of 
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IRF-2 gene into IRF-2-/- B2 B cells.  
Contrary to IgM production, IRF-2-/- B2 cells differentiated to PC-like phenotypic 
cells expressing CD138. Blimp-1 and IRF-2 have similar binding affinities for functionally 
important regulatory sites containing the sequence GAAG (16-18). Therefore, the accelerated 
differentiation to PC-like cells may be attributed to the loss of a competitor, leading to the 
efficient binding of a small amount of Blimp-1 in IRF-2-/- B2 cells to support PC-like 
differentiation, yet not sufficient for antibody production. This possibility may be supported 
by the observation that much vigorous PC differentiation was detected in IRF-2-/- MZB cells, 
as opposed to what takes place in WT mice, even though both expressed comparable levels of 
Blimp-1.  
Recently, it has been reported that spontaneous secretion of low levels of IgM by 
peritoneal B1 cells relies on an IRF4-independent non-classical pathway, whereas that by 
spleen B1 cells does rely on an IRF-4-dependent pathway (31). Therefore, the requirements 
for transcription factors for Ab-production may be distinct in different subsets of B cells. In 
this regard, the different influence of IRF-2 deficiency on Blimp-1 upregulation and IgM 
production by LPS in MZB and B2 cells seems to constitute another example of such a 
different requirement of transcription factors in different B cell subsets. 
In humoral immune responses, B2 cells and MZB cells preferentially respond to TD 
and TI-2 antigens, respectively (25). As in in vitro studies, the IgM response to TD, but not 
TI-2, antigen was severely impaired in IRF-2-/- mice at both 7 d and 14 d after immunization. 
Unlike IgM production, fairly low but significant levels of IgG production was detected at 14 
d, although only an extremely low IgG production was detected at 7 d. Such reduced Ab 
responses at 7 d and 14 d were also observed when µMT mice were reconstituted with 
IRF-2-/- B cells, indicating that IRF-2 plays a role in B cell Ab production in vivo. We 
observed GC formation, and detected the presence of comparable numbers of GC B cells and 
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Tfh cells in the IRF-2-/- spleen. Furthermore, the relative binding activity of anti-TNP IgG is 
nearly equal between IRF-2-/- and WT mice. In addition, IRF-2-/- B2 cells stimulated with 
anti-IgM normally proliferate in the presence of IL-4 and agonistic anti-CD40, but produced 
less IgG1 in response to LPS + IL-4, being due to the inefficient CSR. Therefore, it seems that 
once Tfh is induced, IRF-2-/- B cells get sufficient stimulation signals to develop and sustain 
GCs in vivo but are able to produce only marginal levels of IgG.  
It has been shown that IRF-2-/- mice can produce comparable levels of neutralizing 
IgM and IgG Abs to VSV (21). As IgM production to VSV is T cell-independent (32), our 
result in immunization with TI-2 antigen is consistent with this previous report. However, in 
contrast to our observations, the VSV-specific IgG response, which depends on CD4+ helper 
T cells (33), was reported to be normal in IRF-2-/- mice. The reason for such a discrepancy is 
not clear, but we assume that adjuvant activities of VSV, the virus, and CFA containing 
mycobacteria may contribute to the Ab-producing adaptive immune responses.  
Since antigen-specific IgM production by B2 cells is a key step in the production of 
IgG against TD antigen, the reduced IgG production to TNP-OVA/CFA in IRF-2-/- mice may 
be attributable to a severely impaired extra-follicular IgM response at the earlier time points. 
Given that IgM responses failed to be detected in IRF-2-/- mice even on 14 d, when a 
considerable IgG response was observed, IRF-2 seems to be essential for extra-follicular 
production of IgM and important, but not mandatory, for later IgG production. Related to this 
issue, extra-follicular T cell development has been reported to be crucial to extra-follicular Ab 
responses (34,35). Since IRF-2 was reported to affect the differentiation of helper T cell 
subsets (20), IRF-2 may also contribute to the differentiation and function of extra-follicular 
helper T cells, but not Tfh cells, in addition to B2 cell activation. This possibility should be 
examined in future experiments. 
 In conclusion, our current findings revealed previously unrecognized roles of IRF-2 
 1828 
in B cell activation, particularly that of B2 cells, through regulation of IFNAR signals and 
Blimp-1 expression. Since IRF-2 deficiency affected the function and development of a wide 
array of immune cells, including dendritic cells, NK cells and basophils, future studies of the 
mechanisms for IRF-2 actions in B cells would help us understand those for other 
immunocytes and possibly help uncover a common regulatory principle for multiple cells in 




 antibody, Ab; type I interferon, class switch recombination, CSR; IFN-α/β; type I 
interferon receptor, IFNAR; interferon regulatory factor, IRF; lymph node, LN; 
lipopolysaccharide, LPS; monoclonal antibody, mAb; marginal zone, MZ; marginal zone B, 
MZB; plasma cells, PC; thymidine, TdR; thymus dependent, TD; thymus independent, TI; 
wild type, WT.  
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Fig. 1. Differential regulation of BCR-induced proliferation and Ab production by IRF-2-/-	 
B cells. 
(A) Purified spleen B cells from IRF-2-/- or WT mice were stimulated with various stimuli and 
proliferation was assessed by [3H]-TdR incorporation between 40-48 h of culture. (B) Purified 
spleen B cells from IFNAR-/- and IRF-2-/-IFNAR-/- as well as IRF-2-/- and WT mice were 
stimulated with anti-IgM, and proliferation was then assessed as in (A). (C) Purified splenic 
(left panel) or LN (right panel) B cells from WT, IRF-2-/-, IFNAR-/-, and IRF-2-/- IFNAR-/- 
mice were stimulated with LPS for 3 d. Amounts of IgM in culture supernatant were 
determined by ELISA. Data are shown as the mean ± SD of triplicate cultures and are 
representative of 4 independent experiments. Statistical significance was calculated by 
unpaired Student’s t-test in A, or one-way ANOVA in B and C (** p < 0.01).  
 
Fig. 2. IRF-2 regulates proliferation and Ab production in B2, but not MZB, cells. 
(A) Spleen cells were stained with anti-B220, CD21 and CD23 and analyzed by gating on 
B220+ cells (left panels). Numbers in the figures show the percentages of the respective B cell 
populations in B220+ cells. Cell numbers of each subset are depicted in the right panel. 
Results are the mean ± SD of 12 mice. ** p < 0.01 (t-test) (B) Spleen sections were stained 
with anti-IgM (green) and IgD (blue) (left panels). The thickness of MZ (IgM+IgD-) is shown 
(right panel). MZ is represented between white lines in the pictures. Distances are measured 
by placing perpendicular lines at 50 µm intervals to the white line adjacent to white pulp. 
Horizontal bars represent the mean. Data are representative of 3 independent experiments. ** 
p < 0.01 (t-test)  
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Fig. 3. Defects of IRF-2-/- B2 cells in proliferation, Ab production and CSR. 
(A) Purified B2 and MZB cells from IRF-2-/- and WT mice were cultured with anti-IgM, 
anti-CD40 and LPS. Proliferation was assessed as in Fig. 1A. Data are shown as the mean ± 
SD of triplicate cultures and are representative of 3 independent experiments. ** p < 0.01 
(t-test). (B) Purified B2 cells from IRF-2-/- and WT mice were cultured either alone or with 
anti-IgM, anti-CD40 or IL-4, or the combinations indicated. Proliferation was assessed as in 
Fig. 1A. (C) Purified B2 and MZB cells from IRF-2-/- and WT mice were stimulated with LPS 
for 3 d and the amounts of IgM in supernatants were analyzed by ELISA. (D) Stimulated cells 
in (C) were stained with anti-B220 and anti-CD138. Numbers in figures show the percentage 
of B220lowCD138+ cells. (E) B2 from IRF-2-/- and WT mice were stimulated with LPS in the 
presence or absence of IL-4 for 3 d, followed by intracellular staining with anti-IgG1 after cell 
surface staining with atni-B220. Numbers in figure show the percentage of IgG1+ cells (left 
panels). Percentages of IgG1+ cells are depicted in the right panel. Data are shown as the 
mean ± SD of triplicate cultures and are representative of 3 independent experiments. (F) The 
amounts of IgG1 in supernatant of (E) were assessed by ELISA. Data are shown as the mean 
± SD of triplicate cultures and are representative of 3 independent experiments. * p < 0.05, ** 
p < 0.01 (t-test) 
 
Fig. 4. Impaired upregulation of Prdm1 in IRF-2-/- LN B cells after LPS stimulation and 
rescue of the reduced IRF-2-/- B2 responsiveness by IRF-2 transduction. 
(A) Total RNA was extracted from LN B (top panels) and MZB (bottom panels) cells 
immediately after preparation (d0) or LPS stimulation for 3 d (d3). mRNA expression of Pax5, 
Prdm1, Irf4, Bcl6 and Bach2 was assessed by quantitative RT-PCR. Data are shown as the 
mean ± SD of triplicate cultures and are representative of 3 independent experiments. ** p < 
0.01 (t-test). (B) Expression of IRF-4 protein was determined by Western blot analysis before 
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and after LPS stimulation as in (A). (C) IRF-2 gene containing EGFP was retrovirally 
transduced into IRF-2-/- B2 cells, and upregulations of prdm1and irf2 in EGFP+ cells were 
determined by quantitative RT-PCR 3 d later. (D) Amount of IgM in culture supernatant of 
(C) was measured by ELISA. (E) As in (C), WT B2 cells were subjected to the assay. (F). As 
in (D), the amount of IgM from WT B2 cells that were transduced with IRF-2 gene was also 
determined. Data from (C-F) are shown as the mean ± SD of triplicate cultures and are 
representative of 3 independent experiments. * p < 0.05, ** p < 0.01 (t-test). 
  
Fig. 5. Reduced antibody production in response to TD, but not TI, antigen in IRF-2-/- mice. 
 (A, B) IRF-2-/- and WT mice were immunized ip with TNP-Ficoll (A) or 
TNP-OVA/CFA (B). Sera were collected before and after 7 and 14 d of immunization and 
analyzed for TNP-specific IgM (left panels) and IgG (right panels) production. Results are 
shown as an index, calculated by dividing the half-max O.D. value of serum dilution at 7 d 
and 14 d by that of 0 d. Circles indicate individual mice and horizontal bars represent the 
mean. (C) Affinity of anti-TNP Ab is shown as the relative binding, which was calculated by 
dividing half-maximum serum dilution to TNP5-BSA by that to TNP19-BSA with ELISA. (D) 
Cryosections of spleen from IRF-2-/- and WT mice at 14 d after TNP-OVA/CFA 
immunization were fixed and stained with anti-IgD (green) and PNA (red). Arrows indicate 
GCs. (E) GC B cells in spleen 14 d after stimulation as in (B) were stained with anti-B220, 
PNA and Fas and analyzed by gating on B220+ cells (left panels). Values are the percent of 
B220+PNA+Fas+ cells. The numbers of GC B cells were calculated (right panel). Bar graphs 
show the mean ± SD of 6 mice. (F) Tfh cells in spleen were calculated by the staining with 
anti-CD3ε, CD4 and CXCR5 as in (E). (G) Expressions of IL-21 and Bcl-6 were analyzed by 
quantitative RT-PCR in purified CD4+ T cells 10 d after the immunization. (H) Anti-TNP 
IgM and IgG production was determined 7 and 14 d after immunization as (B) in µMT mouse 
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that had received purified B cells from WT and IRF-2-/- mice 1 d before. To adjust the 
proportion of B2 and MZB cells in IRF-2-/- to that in WT mice, IRF-2-/- LN B cells were 
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